|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
9
|
|
pubmed:dateCreated |
1994-5-19
|
|
pubmed:abstractText |
Previous preclinical studies of combinations of estramustine and vinblastine or paclitaxel (Taxol) have shown that it is possible to achieve a greater than additive cytotoxicity with these antimicrotubule drug combinations. Phase II studies in hormone-refractory prostate cancer have demonstrated clinical antitumor activity of sufficient magnitude to stimulate further laboratory and clinical studies of these drugs combinations.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
0027-8874
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
4
|
|
pubmed:volume |
86
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
688-94
|
|
pubmed:dateRevised |
2007-11-14
|
|
pubmed:meshHeading |
pubmed-meshheading:7908988-Carrier Proteins,
pubmed-meshheading:7908988-Drug Resistance,
pubmed-meshheading:7908988-Estramustine,
pubmed-meshheading:7908988-Female,
pubmed-meshheading:7908988-Gene Expression,
pubmed-meshheading:7908988-Humans,
pubmed-meshheading:7908988-Membrane Glycoproteins,
pubmed-meshheading:7908988-Neoplasm Proteins,
pubmed-meshheading:7908988-Ovarian Neoplasms,
pubmed-meshheading:7908988-P-Glycoprotein,
pubmed-meshheading:7908988-Phenotype,
pubmed-meshheading:7908988-Protein Binding,
pubmed-meshheading:7908988-RNA, Messenger,
pubmed-meshheading:7908988-Tumor Cells, Cultured
|
|
pubmed:year |
1994
|
|
pubmed:articleTitle |
P-glycoprotein binding and modulation of the multidrug-resistant phenotype by estramustine.
|
|
pubmed:affiliation |
Department of Pharmacology, Fox Chase Cancer Center, Philadelphia, PA 19111.
|
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't
|
